DARATUMUMAB
Secondary Amyloidosis
City of Hope Medical Centermonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Secondary Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela City of Hope Medical Center | Phase 2 | CCC |
nc-503 Bellus Health Inc. - a GSK company | Phase 2/3 | NR |
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →